Indonesia’s Innovation Bottleneck: Why Great Science Never Leaves the Lab
Our earlier analyses described a market where demand, spending, regulation and foreign capital are converging. This article asks why Indonesia's investment gaps exist in the first place — and shows that the constraint is not a shortage of science, but what happens, or fails to happen, after the science is done.
The Wrong Diagnosis
A foreign investor encountering Indonesia's life sciences sector for the first time could reasonably assume the constraint is scientific capacity. The data does not support that. Domestic patent filings reached 6,757 in 2024 — a decade high, growing at 14.7% a year since 2015 (DJKI) — and the World Intellectual Property Organization has classified Indonesia as an innovation "overperformer" for four straight years, meaning it converts research inputs into outputs more efficiently than its income level would predict.
What the data does support is a capital problem. National R&D spending sits at roughly 0.28% of GDP, against a 0.70% ASEAN average — and 84.6% of that thin spending is government-funded, versus just 7.3% from the private sector, nearly the inverse of the OECD norm, where firms fund around 70% of national R&D. Indonesia has real science. It has almost no private capital anywhere near that science, and little connecting the two.
Investor Snapshot
| Indicator | Figure | Period | Why it matters to investors |
|---|---|---|---|
| National R&D spending (GERD) | ~0.28% of GDP, vs. 0.70% ASEAN average | 2020–2022 | Indonesia's innovation pipeline starts thin at the source — roughly a quarter of the regional average investment per unit of GDP. |
| R&D funded by government vs. private sector | 84.6% government, 7.3% private | ADB analysis | The opposite of OECD norms (~70% private-funded). Private capital is largely absent — exactly where investors could add the most value. |
| Domestic patent applications | 6,757 filed in 2024, the highest in a decade | 2024–2025, DJKI | Confirms Indonesian inventors are filing at meaningful, growing volume — the base science and invention activity is real. |
| University share of domestic patents | Over 50% of filings, but only ~153 of 4,500+ universities have ever held a patent | DJKI, 2025 | Discovery is concentrated in academia and a small number of institutions — a lab-to-market gap, not a lab shortage. |
| Patents granted to domestic applicants | 566 granted in 2024, against 6,757 applications filed the same year | 2024, BRIN Iptek Indicators | A separate, earlier bottleneck than licensing: examination and grant lag means most filings are not yet patents, let alone commercialized. |
| Share of BRIN's own IP portfolio ever commercialized | Under 10% of 2,500+ patents and other IP assets | As of 2022, BRIN Director of Technology Transfer | A direct statement from Indonesia's national research agency: the gap sits at transfer to industry, not at invention. |
| Global Innovation Index rank | 55th of 139 economies; "overperformer" for 4 straight years | 2025, WIPO | Indonesia converts limited R&D inputs more efficiently than its income level predicts — the constraint is input size, not quality. |
Figures drawn from World Bank, ADB, DJKI, WIPO, and academic research on Indonesian technology commercialization; full citations at the end of this article.
The trend line reinforces the point: Indonesia's GERD has grown from roughly 0.09% of GDP in 2013 to about 0.23–0.28% today — real progress, but still a fraction of South Korea's 4.93%. Regional peers also fund R&D far more privately than Indonesia does: Vietnam (73.0%), Thailand (79.9%) and Singapore (59.6%), against Indonesia's 7.3% (World Bank, ADB).
What this means for investors
- Interpretation
- The constraint is not a shortage of science but a near-total absence of private capital near that science.
- Opportunity
- Sponsored research agreements, corporate–university partnerships, and direct investment in the commercialization infrastructure Indonesia's public research system was never funded to build.
Where the Pipeline Actually Breaks
Moving a lab discovery to market means passing through research, discovery, validation, regulatory clearance, prototyping, GMP-grade manufacturing, clinical or consumer validation, scaled production, distribution, and follow-on investment at every step. The table below maps that sequence against the evidence for Indonesia, drawing on this article and on our earlier macro analysis and sector map.
| Stage | What it looks like in Indonesia | Where the evidence shows it stalls |
|---|---|---|
| 1. Research | R&D concentrated in BRIN and universities; national spending ~0.28% of GDP, 84.6% government-funded. | Thin but functioning — not the primary bottleneck. |
| 2. Discovery | 6,757 patent applications filed in 2024, a decade high; universities account for over half. | Real and growing — not the bottleneck. But only 566 patents were granted in 2024, a first, earlier bottleneck at examination. |
| 3. Validation | Proof-of-concept and TRL testing exists at a small number of leading universities (e.g. ITB's LPIK). | Thin outside a handful of flagship institutions; most universities lack a dedicated validation function. |
| 4. Regulatory | BPOM's 2025 regulatory build-out for biologics and ATMPs codified pathways that barely existed before. | Newly defined but largely untested at scale — a process risk, not a paper gap. |
| 5. Prototype | Example: ITB's TRL-7 autonomous electric transport technology, patent-protected and tested in a real environment. | Stall Production did not proceed due to inadequate investment despite reaching TRL 7. |
| 6. GMP / manufacturing-grade production | Independent, multi-client GMP and cleanroom capacity remains limited. | Stall One of the clearest, most consistently cited stalls across our research. |
| 7. Clinical / consumer validation | A functioning ~US$1.2bn CRO market exists, concentrated in Jakarta, Surabaya and Bandung. | Capacity exists but is geographically and institutionally concentrated. |
| 8. Manufacturing (at scale) | 85% of active pharmaceutical ingredients are imported even though 95% of finished-dose products are made domestically. | Stall The single largest, most precisely quantified stall we have found. |
| 9. Distribution | Well-developed for established consumer categories (Wardah, Sido Muncul, Kalbe Farma). | Functions well once a product exists — not where projects die. |
| 10. Investment (follow-on capital) | Fewer than 10% of BRIN's 2,500+ IP assets had been commercialized as of 2022, per BRIN's own Director of Technology Transfer. | Stall Capital does not reliably follow validated IP — the clearest quantified evidence of the gap. |
Sources: DJKI 2024–2025 patent filing and grant data; BRIN Director of Technology Transfer statement via Tempo (2023); LIPI/BRIN patent-licensing data compiled by Rochman (2018) via Dzakiy (2024).
Two patterns stand out. Research and discovery are not where Indonesian innovation stalls — the pipeline breaks down in the middle and late stages: validation infrastructure outside a small number of flagship universities, GMP-grade manufacturing, and, most starkly, the shift from a legally protected invention to a licensed, commercially deployed one.
Speaking at a BRIN seminar in April 2023, Edi Hilmawan, BRIN's Director of Technology Transfer and Audit Systems, said fewer than 10% of the more than 2,500 IP assets BRIN managed through 2022 had been commercialized (Tempo). Older, narrower data point the same way: LIPI/BRIN records compiled by researcher Rochman in 2018 show only about 5% of the 159 patents registered in 2017 were ever licensed by industry, and none of the patents registered in 2013 or 2014 (per a 2024 ITB doctoral dissertation). Six years apart, both figures describe the same pattern — most registered, legally protected Indonesian inventions never reach industry.
What this means for investors
- Investor implication
- A large, underexploited inventory of Indonesian IP likely exists and is accessible to an investor equipped to identify and license it.
- Opportunity
- IP scouting, licensing partnerships, and direct investment in the technology-transfer, incubation and proof-of-concept functions Indonesian institutions largely lack.
A Concrete Example of the Stall
Institut Teknologi Bandung (ITB) — widely regarded as Indonesia's most developed university in technology commercialization — developed an autonomous, electrically powered elevated transport technology (patent ID 202001484A). By 2022 it had reached Technology Readiness Level 7: a working prototype tested successfully in a real operational environment, one step from commercial deployment (Dzakiy, 2024).
Production never proceeded — not because the technology failed, and not because of a regulatory barrier, but for lack of investment at exactly the stage a validated prototype needs capital to scale into manufacturing. Researchers call this the "valley of death": public funding already spent, private investment not yet arrived, technically successful projects stalling for want of a bridge.
The same pattern appears in life sciences specifically: 85% of active pharmaceutical ingredients are imported even though 95% of finished-dose pharmaceutical products are already made domestically, according to Indonesia's Minister of Industry — strong downstream manufacturing and almost no upstream ingredient production, a gap in the middle of the value chain rather than at either end.
What this means for investors
- Interpretation
- The gap is not evenly distributed across the value chain — it clusters at the prototype-to-manufacturing and ingredient-to-production junctures.
- Opportunity
- Scale-up financing, GMP/CDMO infrastructure investment, and API or raw-material manufacturing partnerships.
The Gap Is Recognized — and Already Being Funded, Just Not at Scale
Indonesian policymakers are not unaware of this problem. The Kedaireka Matching Fund, launched in 2020 by what is now the Ministry of Higher Education, Science and Technology, pairs university research with industry co-funding. Funded proposals grew from 427 in 2021 to 1,093 in 2022, and the program remained active through at least mid-2025, with 2025-cycle recipients announced that July. Over the same period, Indonesia's ranking on the Global Innovation Index's university–industry collaboration sub-indicator rose from 33rd (2020) to 5th (2023) — measurable progress in exactly the linkage this article identifies as the constraint.
The program has produced real, sustained life-sciences outcomes. Universitas Syiah Kuala's Atsiri Research Center, with industry partner Focustindo Cemerlang Bogor, launched an anti-aging serum in November 2022 under Kedaireka funding, then four more patchouli-based skincare products in November 2024. IPB University signed three technology-licensing agreements in 2026, including a Kedaireka-supported feed-wafer technology from its Institute for Agromaritime Development.
These examples matter less for their scale than for what they show: when Indonesia builds a matching mechanism connecting university research to industry co-investment, commercialization happens. IPB's 2024 Kedaireka allocation — Rp12 billion in government funding matched to Rp24 billion in total project value across 20 proposals — is a fraction of a single foreign biotech investment, such as the roughly US$30 million Takeda commitment we examined earlier. The mechanism already exists in prototype form; it operates several orders of magnitude below what the sector gaps would require to close.
What this means for investors
- Investor implication
- A foreign investor entering through an existing matching-fund-style partnership inherits a working mechanism rather than building one from scratch.
- Opportunity
- Co-investment alongside Kedaireka-style structures, and direct partnership with university technology transfer offices such as ITB's LPIK or IPB's LPA2I.
What This Means for Investors
Indonesia's research and invention base is larger and more active than its finished-product base would suggest, and the gap between the two is structural, government-acknowledged, and already being addressed at small scale:
- Opportunity: a meaningful pool of patented, unlicensed intellectual property likely exists across universities and BRIN, largely unexploited for want of a commercialization partner.
- Momentum: the Kedaireka matching-fund model and BRIN's consolidation of Indonesia's research institutions are direct policy responses to this gap, both still early in their scale-up.
- Competitive field: private R&D funding is only 7.3% of the national total, so a foreign investor faces little sophisticated domestic commercialization capital — but existing matching-fund infrastructure and technology transfer offices offer a partner rather than a blank slate.
- Barrier: the gap is multi-staged — validation, GMP-grade manufacturing and follow-on investment are all thin — so funding a single stage is unlikely to fully de-risk a project.
- Entry models: licensing partnerships with universities holding unexploited patents; co-investment alongside matching-fund structures; direct investment in proof-of-concept, GMP or CDMO infrastructure; and sponsored research agreements.
The Missing Intermediary
What's missing across every stage is an intermediary that bridges laboratory and industry — the function a Technology Transfer Office performs at the few universities sophisticated enough to run one. Most Indonesian research institutions don't have it at all. Where it exists — at ITB, at IPB, in pockets of BRIN — it demonstrably works, producing licensing agreements and matching-fund successes, and, per this article, at least one large-scale documented stall precisely because that function wasn't sufficiently resourced at the critical moment.
SciencePreneur operates in that same intermediary position for Indonesia's life sciences sector: identifying research with genuine commercial and industrial relevance and connecting it to the regulatory pathways, the sector-specific investment gaps, and the foreign capital and expertise Indonesian public research funding was never designed to supply on its own.
Where This Leaves the Investor
Indonesia's life sciences opportunity is not constrained by a shortage of science. It is constrained by what happens — or does not happen — between a validated discovery and a manufactured, distributed product. Funding more research does not close this gap; Indonesia already produces more patentable invention than its commercialization infrastructure can absorb. What closes it is capital and partnership placed specifically at validation, prototype-to-manufacturing, and licensing — the exact points this article's data identifies as the stall.
Email: admin@sciencepreneur.com · WhatsApp: +62 852-8619-5334 · Website: www.sciencepreneur.com
References
- World Bank — Research and development expenditure (% of GDP), Indonesia, World Development Indicators.
- Asian Development Bank — sector assessment on Indonesia's GERD composition and ASEAN comparison.
- R&D World Institute — 2022 Global R&D Funding data, Indonesia ranking and GDP ratio, via Databoks/Katadata.
- Directorate General of Intellectual Property (DJKI), Indonesia — patent filing statistics and Director of Patents Sri Lastami's statement on 2015–2025 growth trends, dgip.go.id, 2025.
- DJKI — 2025 domestic patent filing count and university patent-holder statistics, via Hakteknas coverage referencing DJKI and BRIN data, August 2026.
- National Research and Innovation Agency (BRIN) — "Indikator Ilmu Pengetahuan, Teknologi, dan Inovasi Indonesia 2025," via Hakteknas coverage for 2024 domestic patent grant figures.
- Tempo — statement by Edi Hilmawan, BRIN Director of Technology Transfer and Audit Systems, on IP commercialization rates, BRIN seminar coverage, April 2023.
- World Intellectual Property Organization (WIPO) — Global Innovation Index 2025, Indonesia country profile, published September 2025.
- Dzakiy, Uruqul Nadhif (2024) — "Technology Commercialization at an Indonesian University: A Practical Model and Integrated Policies and Supports," Doctoral Dissertation, ITB — including LIPI/BRIN patent-licensing data compiled by Rochman (2018) and the ITB microcapsule case study.
- Ministry of Higher Education, Science and Technology (Kemdiktisaintek) — Kedaireka Matching Fund program data, 2021–2024 proposal counts, and coverage of the Atsiri Research Center–Focustindo Cemerlang partnership, kemdiktisaintek.go.id.
- Kedaireka Program Dana Padanan official platform (backoffice.kedaireka.id) — 2025 cycle: call for proposals opened October 2024, funding recipients announced July 2025.
- Universitas Syiah Kuala — official coverage of the Atsiri Research Center's Kedaireka-funded skincare product launches (2022 and 2024), usk.ac.id.
- IPB University — "IPB University Accelerates Research Commercialization Through the Signing of Technology Licensing Agreements and Royalty Payments," official university news, 2026.
- Ministry of Industry (Kemenperin) — statement on pharmaceutical API import dependency and domestic finished-dose production.
Sources and data notes
This article's central commercialization-gap statistic — fewer than 10% of BRIN's IP portfolio commercialized as of 2022 — comes from a direct statement by BRIN's own Director of Technology Transfer, reported by Tempo in April 2023, and is corroborated by older, independently compiled data showing similarly low patent-to-license rates in 2013–2017. SciencePreneur was not able to locate a more recent, consolidated commercialization-rate figure than 2022 — itself consistent with this article's argument that these outcomes are not closely or regularly tracked in Indonesia. R&D spending figures vary slightly by source and year (approximately 0.23–0.28% of GDP) depending on methodology; ASEAN and OECD comparisons are drawn from ADB and academic secondary analysis rather than a single primary dataset. Patent filing and grant figures are drawn directly from DJKI and BRIN's own published statistics.